Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

Thu, 12 Feb 2026 09:00:00 -0500

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.

What:

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany.

Klinikum Fürth is the first hospital in Germany to establish a leading heart rhythm program that incorporates the Genesis Robotic Magnetic Navigation System, advanced robotic technology that establishes a new standard of care for patients with arrhythmias. Physicians at Klinikum Fürth have successfully treated their first patients, with a wide range of arrhythmias, leveraging the

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Mon, 09 Feb 2026 08:06:00 -0500

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Mon, 09 Feb 2026 08:06:00 -0500

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Mon, 09 Feb 2026 08:06:00 -0500

Stereotaxis receives FDA approval for robotic ablation catheter

Tue, 06 Jan 2026 08:02:34 -0500

Stereotaxis (NYSE: STXS) announced it received U.S. Food and Drug Administration approval for its MAGiC Magnetic Interventional Ablation Catheter on January 6.

The robotically-navigated magnetic ablation catheter is designed to perform cardiac ablation procedures that treat heart arrhythmia. The device uses computer-controlled magnetic fields to navigate and is intended for patients with congenital heart disease where conventional manual catheter access is limited due to anatomic abnormalities or previous surgical interventions.

The catheter is indicated for cardiac electrophysiological mapping, delivering diagnostic pacing stimuli, and creating endocardial lesions to treat supraventricular tachycardia conditions including macroreentrant atrial tachycardia, focal atrial tachycardia, atrioventricular nodal reentrant tachycardia,

Stereotaxis receives FDA approval for robotic ablation catheter

Tue, 06 Jan 2026 08:02:34 -0500

Stereotaxis (NYSE: STXS) announced it received U.S. Food and Drug Administration approval for its MAGiC Magnetic Interventional Ablation Catheter on January 6.

Stereotaxis receives FDA approval for robotic ablation catheter

Tue, 06 Jan 2026 08:02:34 -0500

Stereotaxis (NYSE: STXS) announced it received U.S. Food and Drug Administration approval for its MAGiC Magnetic Interventional Ablation Catheter on January 6.

Stereotaxis receives FDA approval for robotic ablation catheter

Tue, 06 Jan 2026 08:02:34 -0500

Stereotaxis (NYSE: STXS) announced it received U.S. Food and Drug Administration approval for its MAGiC Magnetic Interventional Ablation Catheter on January 6.

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter